Drug news

Sevikar HCT (Daiichi Sankyo) now available in the UK

Read time: 1 mins

Last updated:25th Nov 2011

Published:25th Nov 2011

Source: Pharmawand

Sevikar HCT (olmesartan medoxomil, amlodipine besylate plus hydrochlorothiazide) from Daiichi Sankyo Europe, the first three-in-one pill to treat Hypertension, has been launched in the UK. Currently around 2 million people in the UK need to take three or more pills daily to treat their hypertension. The drug is approved in the USA and available as Tribenzor.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Positive phase III topline results from Study 501 evaluating lumateperone as adjunctive therapy in patients with major depressive disorder

Intra-Cellular Therapies, Inc. a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announced positive topline results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)

2 mins

Drug news

FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, announced the FDA approved Dovato (dolutegravir/lamivudine) for the treatment of HIV-1 infection in adolescents 12 years of age and older and weighing at least 25 kg with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Dovato

1 min

Drug news

Imfinzi (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 phase III trial

Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC)

1 min

See all news